Rotigotine

Trade names

• NEUPRO

Actions

• Agonist of the D1, D2, D3, and, to a lesser extent, D4 and D5 dopamine receptors with highest affinity for the D3 subtype.

Route of Administration

Transdermal patch

Bioavailability

37%

Plasma protein binding

92%

Half-life

5-7 hours

Metabolism

Hepatic

Elimination

Renal 71%, biliary 23%

Important side-effects

Excessive sleepiness.

Impaired impulse control (gambling, compulsive shopping, compulsive eating, etc).

Hypersexuality.

Confusion, hallucinations, delusions, psychosis.

Dyskinesia.

Orthostatic hypotension.

Recommended dose

Start with 2 mg / 24 hours patch.

Increase by weekly increments of 2 mg / 24 hours.

Maximum dose is 16 mg / 24 hours.

Renal impairment

No dose adjustment is necessary.

Hepatic impairment

No dose adjustment is necessary in patients with mild and moderate hepatic dysfunction.

Insufficient data exist on the safety of rotigotine in patients with severely impaired hepatic function..